Vertex evaluating combination treatment for CF

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) began a Phase IIa trial to evaluate a combination of two investigational cystic fibrosis transmembrane conductance regulators ( CFTR), VX-770 and VX-809, for cystic fibrosis. The three-part, double-blind, placebo-controlled trial will enroll up to 160 patients with two copies of the delta F508 CFTR mutation to evaluate safety and CFTR function as measured by sweat chloride. Interim data from about 60 patients are expected in 1H11. ...